Former Spectranetics executives indicted
This article was originally published in The Gray Sheet
Executive Summary
Three former executives and one contractor with Spectranetics face possible jail time and fines based on a twelve-count indictment on allegations that the company illegally imported unapproved devices into the U.S., the Colorado U.S. Attorney's Office and FDA's Office of Criminal Investigations announced Aug. 30. George John Schulte, former CEO of the excimer laser system maker, Obinna Adhigije, former VP of business development, Trung Pham, former business development manager, and Hernan Ricaurte, the contractor, are charged with conspiring to import devices based on false declarations, to introduce devices in the U.S. market without FDA approval or clearance, and to promote the devices for unauthorized uses, among other detailed counts. Spectranetics itself settled with the Department of Justice for $5 million on similar charges last December (1"The Gray Sheet" Jan. 4, 2010)
You may also be interested in...
Spectranetics settlement
Excimer laser system maker Spectranetics will pay $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims that it illegally imported and sold unapproved medical devices from overseas manufacturers, failed to meet clinical trial reporting requirements and promoted certain products for unapproved uses, the Justice Department announced Dec. 29. In addition to the civil settlement, the firm entered into a non-prosecution agreement and corporate integrity agreement to resolve the matter. According to the non-prosecution agreement, Spectranetics accepts responsibility for its conduct and will not be criminally prosecuted. As part of the integrity agreement, the firm's clinical trial records will be audited by an independent review organization "to insure compliance with FDA rules - including reporting of adverse events," HHS Inspector General Daniel Levinson said. FDA and U.S. Immigration and Customs Enforcement had served Spectranetics with a search warrant requesting information related to the matter in September 2008 (1"The Gray Sheet" Sept. 15, 2008)
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.